What does it look like to lose your understanding of the world? Drawings from patients with semantic dementia reveal a transmodal graded loss of concept knowledge: doi.org/10.3758/s13421… with Cambridge FTD

✨ Congratulations Adam Dyer on receiving Faculty of Health Sciences Dean’s Award 🏆 such an exciting project investigating viral exposure 🦠 in Alzheimer’s disease 🧠 Nollaig Bourke TCD Medical Gerontology Sean Kennelly Cliona O'Farrelly Matt McElheron ✨

👏Congratulations to ⁦Tallaght University Hospital (TUH)⁩ memory service colleague ⁦Helena Dolphin⁩ on her tour de force talk on current and novel therapies in AD and dementia at ⁦British Geriatrics Society⁩ conference today in Birmingham.

A phase 2a study published in Nature Medicine found a novel #neuroprotective Alzheimer's drug developed by ADDF-funded PharmatrophiX met its primary endpoint. Learn more about how these findings are emblematic of the new era of #Alzheimers research here: bit.ly/3QTvuZ7

Digital Gait Labs are looking for developers in the areas listed below. Come and see how we are applying state of the art AI and AR in the digital health field. Email enquires to [email protected]

Eisai requests FDA approval of maintenance and subcutaneous Leqembi doses; donanemab AdComs will convene on June 10. #alzheimersdisease
ow.ly/annS50RKW3U

Updated Lecanemab safety results

Just published in Alzheimer's Research & Therapy.

This analysis now also includes the open-label extension (OLE) study of the FDA-approved anti-amyloid drug Lecanemab (Leqembi).

Main new findings:

1⃣ There were 9 deaths during the OLE, with 4

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease | Alzheimer's Research & Therapy | Full Text alzres.biomedcentral.com/articles/10.11…

We always knew there was an increased risk, but this study concludes that APOE4 homozygotes represent a genetic form of Alz Dx with nearly all having positive CSF Amyloid, and 75% being Amy-PET positive by age 65. Age of symptom onset also earlier. nature.com/articles/s4159…

Scientists identify the brain cells that regulate inflammation, and pinpoint how they keep tabs on the immune response go.nature.com/4dmc9Jo

Exercising in Midlife May 'Reverse' Years of Inactivity, Large Study Finds sciencealert.com/exercising-in-…

The Alzheimer's disease 2024 drug development pipeline

An often heard critique is that the Alzheimer field is too “amyloid-centric”. The Figure below actually shows a well-diversified drug pipeline, which is highly needed.

The mechanisms of action (CADRO) for agents currently

👏Congratulations to HealthResearchBoard ICAT research fellow Adam Dyer, Nollaig Bourke, TCD Medical Gerontology, and Tallaght University Hospital (TUH) colleagues for making list of most cited papers in JAMDA from 2022 with our paper: sciencedirect.com/science/articl…

How the way you walk tells the story of your health. Your gait is a fundamental clinical measure of your health, including future changes in cognitive and emotional health, writes Aidan Boran Dublin City University Insight SFI Research Centre Science Foundation Ireland rte.ie/brainstorm/202…

Fantastic demo ⁦Gillian Harte⁩, ⁦Aidan Boran⁩ &Naomi of #Gaitkeeper which provides valid & objective measurements to detect changes&declining health in our older people&guide earlier intervention ⁦Tallaght University Hospital (TUH)⁩ ⁦Aine O'Brien⁩ ⁦⁦Eimear Walsh⁩

Putting the spotlight on the need for increased trial opportunities for those living with dementia and research priorities for Lewy Body Dementia: Iracema Leroi (DTI Lead) and Rachel Fitzpatrick (DTI ECR) at ADI Krakow this week #ADI2024 HealthResearchBoard Dementia Research Network Ireland Irina Kinchin

PLEASE LISTEN 🧵
This is Prof Ronan Collins Dr.Ronan collins (National Clinical Lead Stroke) scathing criticism of Dept of Health/HSE Ireland treatment of 850,000 people in Ireland living with neurology/neurodegenerative conditions and the moratorium on recruitment …

Our friends in Brain Health ARC Scotland are hosting a webinar on starting out in the brain health field!

Join speaker Dr David Koss for valuable advice & strategies for an academic career in brain health!

📅 May 3rd 2024
⏰ 13:00-14:00
Register: forms.office.com/e/23qTHgS31r

Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies | The British Journal of Psychiatry | Cambridge Core - bit.ly/4b3u8Cr

‘Significant breakthrough’ as new AI app helping doctors at Tallaght University Hospital diagnose early Alzheimer's independent.ie/regionals/dubl…